{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:58:00Z","timestamp":1781647080295,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R21CA228099-01A1"],"award-info":[{"award-number":["1R21CA228099-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009054"],"award-info":[{"award-number":["T32CA009054"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Naational Institute of Health","award":["P30CA062203"],"award-info":[{"award-number":["P30CA062203"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-18362970"],"award-info":[{"award-number":["RS-2025-18362970"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-25427881"],"award-info":[{"award-number":["RS-2025-25427881"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nano Convergence"],"DOI":"10.1186\/s40580-026-00543-3","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:30:47Z","timestamp":1775539847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal gene and targeted drug therapy for chronic myelogenous leukemia using BIM\/MCL-1 chimeric nanoparticle: computational target analysis and therapeutic validation"],"prefix":"10.1186","volume":"13","author":[{"given":"Margaret L.","family":"Lugin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Katritsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woochang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela G.","family":"Fleischman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namshik","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-6995","authenticated-orcid":false,"given":"Young Jik","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"543_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"F. Sanchez-Vega, M. Mina, J. Armenia, W.K. Chatila, A. Luna, K.C. La, S. Dimitriadoy, D.L. Liu, H.S. Kantheti, S. Saghafinia, D. Chakravarty, Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173, 321\u2013337 (2018). https:\/\/doi.org\/10.1016\/j.cell.2018.03.035","journal-title":"Cell"},{"key":"543_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1744-3","volume":"575","author":"N Vasan","year":"2019","unstructured":"N. Vasan, J. Baselga, D.M. Hyman, A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019). https:\/\/doi.org\/10.1038\/s41586-019-1744-3","journal-title":"Nature"},{"key":"543_CR3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/315550a0","volume":"315","author":"E Shtivelman","year":"1985","unstructured":"E. Shtivelman, B. Lifshitz, R.P. Gale, E. Canaani, Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550\u2013554 (1985). https:\/\/doi.org\/10.1038\/315550a0","journal-title":"Nature"},{"key":"543_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3523718","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Y. Ben-Neriah, G.Q. Daley, A. Mes-Masson, O.N. Witte, D. Baltimore, The chronic myelogenous leukemia-specific P210 protein is the product of the bcr-abl hybrid gene. Science 233, 212\u2013214 (1986). https:\/\/doi.org\/10.1126\/science.3523718","journal-title":"Science"},{"key":"543_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, J.M. Ford, R. Capdeville, M. Talpaz, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1038\u20131042 (2001). https:\/\/doi.org\/10.1056\/NEJM200104053441401","journal-title":"N. Engl. J. Med."},{"key":"543_CR6","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"J.E. Cortes, G. Saglio, H.M. Kantarjian, M. Baccarani, J. Mayer, C. Boqu\u00e9, N.P. Shah, C. Chuah, L. Casanova, B. Bradley-Garelik, G. Manos, Final 5-Year study results of DASISION: the Dasatinib versus Imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J. Clin. Oncol. 34, 2333\u20132340 (2016). https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J. Clin. Oncol."},{"key":"543_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00822-4","volume":"13","author":"J Senapati","year":"2023","unstructured":"J. Senapati, K. Sasaki, G.C. Issa, J.H. Lipton, J.P. Radich, E. Jabbour, H.M. Kantarjian, Chronic myeloid leukemia 2023: update on diagnosis, therapy, and monitoring. Blood Cancer J. 13, 58 (2023). https:\/\/doi.org\/10.1038\/s41408-023-00822-4","journal-title":"Blood Cancer J."},{"key":"543_CR8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3532","volume":"104","author":"RT Silver","year":"2004","unstructured":"R.T. Silver, M. Talpaz, C.L. Sawyers, B.J. Druker, A. Hochhaus, C.A. Schiffer, F. Guilhot, J.M. Goldman, B.D. Smith, M. Mone, T. Kranhnke, Imatinib mesylate (Gleevec) for hepatocellular carcinoma: a phase II study. Blood 104, 23 (2004). https:\/\/doi.org\/10.1182\/blood-2003-10-3532","journal-title":"Blood"},{"key":"543_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41409-020-01031-6","volume":"56","author":"S Mizuno","year":"2021","unstructured":"S. Mizuno, M. Yanada, K. Kawamura, M. Masuko, N. Uchida, Y. Ozawa, K. Iwato, K. Ohashi, K. Ikegame, S.W. Kim, M. Tanaka, Impact of pre-transplant tyrosine kinase inhibitor on outcomes of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 56, 232\u2013242 (2021). https:\/\/doi.org\/10.1038\/s41409-020-01031-6","journal-title":"Bone Marrow Transplant."},{"key":"543_CR10","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1002\/cam4.2173","volume":"8","author":"J Chang","year":"2019","unstructured":"J. Chang, D. Douer, I. Aldoss, G. Vahdani, A.R. Jeong, Z. Ghaznavi, S. Zhang, G. Yaghmour, K.J. Lee, A. Weissman, M. Akhtari, Tyrosine kinase inhibitor utilize in older patients with chronic myeloid leukemia. Cancer Med. 8, 2832\u20132839 (2019). https:\/\/doi.org\/10.1002\/cam4.2173","journal-title":"Cancer Med."},{"key":"543_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2018.1472236","volume":"17","author":"M Breccia","year":"2018","unstructured":"M. Breccia, F. Efficace, A. Iurlo, L. Luciano, E. Abruzzese, A. Gozzini, P. Pregno, M. Tiribelli, G. Rosti, G. Minotti, Clinical management of cardiovascular risk in patients with chronic-phase CML. Expert Opin. Drug Saf. 17, 623\u2013628 (2018). https:\/\/doi.org\/10.1080\/14740338.2018.1472236","journal-title":"Expert Opin. Drug Saf."},{"key":"543_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00277-014-2239-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"B. Chereda, J.V. Melo, Natural course and biology of CML. Ann. Hematol. 94, 107\u2013121 (2015). https:\/\/doi.org\/10.1007\/s00277-014-2239-z","journal-title":"Ann. Hematol."},{"key":"543_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"AE Osman","year":"2021","unstructured":"A.E. Osman, M.W. Deininger, Resistance in chronic myeloid leukemia: lessons from the past and future prospects. Blood Rev. 49, 100825 (2021). https:\/\/doi.org\/10.1016\/j.blre.2021.100825","journal-title":"Blood Rev."},{"key":"543_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/bjh.16488","volume":"190","author":"G Saglio","year":"2020","unstructured":"G. Saglio, R.P. Gale, Treatment-free remission in chronic myeloid leukemia. Br. J. Haematol. 190, 318\u2013327 (2020). https:\/\/doi.org\/10.1111\/bjh.16488","journal-title":"Br. J. Haematol."},{"key":"543_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"D.M. Ross, S. Branford, J.F. Seymour, A.P. Schwarer, C. Arthur, D.T. Yeung, P. Dang, J.M. Goyne, C. Slader, R.J. Filshie, A.K. Mills, Safety and efficacy of Imatinib cessation for CML patients with stable undetectable molecular disease. Blood 122, 515\u2013522 (2013). https:\/\/doi.org\/10.1182\/blood-2013-02-483750","journal-title":"Blood"},{"key":"543_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-021-00895-x","volume":"22","author":"N Cerveira","year":"2021","unstructured":"N. Cerveira, S. Bizarro, M.R. Teixeira, J.M. Mariz, Genetic basis of BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Curr. Treat. Options Oncol. 22, 1\u201312 (2021). https:\/\/doi.org\/10.1007\/s11864-021-00895-x","journal-title":"Curr. Treat. Options Oncol."},{"key":"543_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-016-0306-0","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"L. Caldemeyer, M. Dugan, J. Edwards, L. Akard, Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr. Hematol. Malig. Rep. 11, 71\u201379 (2016). https:\/\/doi.org\/10.1007\/s11899-016-0306-0","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"543_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrclinonc.2016.147","volume":"14","author":"JS Lopez","year":"2017","unstructured":"J.S. Lopez, U. Banerji, Combine and conquer: challenges for combinatorial anticancer therapies. Nat. Rev. Clin. Oncol. 14, 57\u201366 (2017). https:\/\/doi.org\/10.1038\/nrclinonc.2016.147","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"543_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8412","volume":"11","author":"A Lin","year":"2019","unstructured":"A. Lin, C.J. Giuliano, A. Palladino, K.M. John, C. Abramowicz, M.L. Yuan, E.L. Sausville, D.A. Lukow, L. Liu, A.R. Chait, Z.C. Galluzzo, Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11, eaaw8412 (2019). https:\/\/doi.org\/10.1126\/scitranslmed.aaw8412","journal-title":"Sci. Transl. Med."},{"key":"543_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.cels.2018.03.001","volume":"6","author":"JK Huang","year":"2018","unstructured":"J.K. Huang, D.E. Carlin, M.K. Yu, W. Zhang, J.F. Kreisberg, P. Tamayo, T. Ideker, Systematic dissection of cancer cell vulnerabilities through network-based elucidation of compound-target interactions. Cell Syst. 6, 484\u2013495 (2018). https:\/\/doi.org\/10.1016\/j.cels.2018.03.001","journal-title":"Cell Syst."},{"key":"543_CR21","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.0901538106","volume":"106","author":"M Brehme","year":"2009","unstructured":"M. Brehme, O. Hantschel, J. Colinge, I. Kaupe, M. Planyavsky, T. K\u00f6cher, K. Mechtler, K.L. Bennett, G. Superti-Furga et al., Charting the global cellular responses to Imatinib in leukemic cells by proteomics, siRNA screening, and network analysis. Proc. Natl. Acad. Sci. U.S.A. 106, 7414\u20137419 (2009). https:\/\/doi.org\/10.1073\/pnas.0901538106","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"543_CR22","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.1021\/acsnano.6b03889","volume":"10","author":"CA Hong","year":"2016","unstructured":"C.A. Hong, S.K. Cho, J.A. Edson, J. Kim, D. Ingato, B. Pham, A. Chuang, D.A. Fruman, Y.J. Kwon, Enhancing cancer therapy using siRNA delivery systems. ACS Nano 10, 8705\u20138714 (2016). https:\/\/doi.org\/10.1021\/acsnano.6b03889","journal-title":"ACS Nano"},{"key":"543_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-11-204","volume":"11","author":"J Rubert","year":"2011","unstructured":"J. Rubert, Z. Qian, R. Andraos, D.A. Guthy, T. Radimerski, BIM and PUMA mediate imatinib-induced apoptosis in leukemia cells. BMC Cancer 11, 1\u201314 (2011). https:\/\/doi.org\/10.1186\/1471-2407-11-204","journal-title":"BMC Cancer"},{"key":"543_CR24","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1111\/j.1742-4658.2009.07323.x","volume":"276","author":"AS Gillings","year":"2009","unstructured":"A.S. Gillings, K. Balmanno, C.M. Wiggins, M. Johnson, S.J. Cook, Apoptosis and autophagy: BIM as a mediator of anticancer drug-induced cell death. FEBS J. 276, 6050\u20136062 (2009). https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07323.x","journal-title":"FEBS J."},{"key":"543_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1128\/MCB.21.3.854-864.2001","volume":"21","author":"T Shinjyo","year":"2001","unstructured":"T. Shinjyo, R. Kuribara, T. Inukai, H. Hosoi, T. Kinoshita, A. Miyajima, P.J. Houghton, A.T. Look, K. Ozawa, T. Inaba, Downregulation of Bim, a proapoptotic member of the Bcl-2 family, is required for survival of BCR-ABL-expressing cells. Mol. Cell Biol. 21, 854\u2013864 (2001). https:\/\/doi.org\/10.1128\/MCB.21.3.854-864.2001","journal-title":"Mol. Cell Biol."},{"key":"543_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/2159-8290.CD-11-0155","volume":"1","author":"AC Faber","year":"2011","unstructured":"A.C. Faber, R.B. Corcoran, H. Ebi, L.V. Sequist, B.A. Waltman, E. Chung, J. Incio, S.R. Digumarthy, S.F. Pollack, Y. Song, A. Muzikansky, BIM expression as a predictor of response to kinase inhibitors. Cancer Discov. 1, 352\u2013365 (2011). https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0155","journal-title":"Cancer Discov."},{"key":"543_CR27","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","volume":"24","author":"R Kuribara","year":"2004","unstructured":"R. Kuribara, H. Honda, H. Matsui, T. Shinjyo, T. Inukai, K. Sugita, S. Nakazawa, H. Hirai, K. Ozawa, T. Inaba, Roles of Bim in apoptosis of hematopoietic cells. Mol. Cell Biol. 24, 6172\u20136183 (2004). https:\/\/doi.org\/10.1128\/MCB.24.14.6172-6183.2004","journal-title":"Mol. Cell Biol."},{"key":"543_CR28","doi-asserted-by":"publisher","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-1244","volume":"65","author":"KJ Aichberger","year":"2005","unstructured":"K.J. Aichberger, M. Mayerhofer, M.T. Krauth, A. Vales, R. Kondo, S. Derdak, W.F. Pickl, E. Selzer, M. Deininger, B.J. Druker, C. Sillaber, Low-level expression of proapoptotic Bim in chronic myeloid leukemia. Cancer Res. 65, 9436\u20139444 (2005). https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1244","journal-title":"Cancer Res."},{"key":"543_CR29","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0606623103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"J. Kuroda, H. Puthalakath, M.S. Cragg, P.N. Kelly, P. Bouillet, D.C. Huang, S. Kimura, O.G. Ottmann, B.J. Druker, A. Villunger, A.W. Roberts, Bim and Bad mediate imatinib-induced apoptosis in cytotoxic T cells. Proc. Natl. Acad. Sci. U.S.A. 103, 14907\u201314912 (2006). https:\/\/doi.org\/10.1073\/pnas.0606623103","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"543_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag2335","volume":"8","author":"BZ Carter","year":"2016","unstructured":"B.Z. Carter, P.Y. Mak, H. Mu, H. Zhou, D.H. Mak, W. Schober, J.D. Leverson, B. Zhang, R. Bhatia, X. Huang, J. Cortes, Combined targeting of BCL-2 and BCR-ABL eliminates leukemia stem cells. Sci. Transl. Med. 8, 355ra117 (2016). https:\/\/doi.org\/10.1126\/scitranslmed.aag2335","journal-title":"Sci. Transl. Med."},{"key":"543_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2013.01.004","volume":"12","author":"DJ Goff","year":"2013","unstructured":"D.J. Goff, A. Sadarangani, H.J. Chun, C.L. Barrett, M. Krajewska, H. Leu, J. Low-Marchelli, W. Ma, A.Y. Shih, J. Wei, D. Zhai, A high-throughput screen for compounds that target leukemia stem cells. Cell Stem Cell 12, 316\u2013328 (2013). https:\/\/doi.org\/10.1016\/j.stem.2013.01.004","journal-title":"Cell Stem Cell"},{"key":"543_CR32","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"D. Szklarczyk, A.L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, M. Simonovic, N.T. Doncheva, J.H. Morris, P. Bork, L.J. Jensen, STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019). https:\/\/doi.org\/10.1093\/nar\/gky1131","journal-title":"Nucleic Acids Res."},{"key":"543_CR33","doi-asserted-by":"publisher","first-page":"D684","DOI":"10.1093\/nar\/gkm795","volume":"36","author":"M Kuhn","year":"2007","unstructured":"M. Kuhn, C. von Mering, M. Campillos, L.J. Jensen, P. Bork, STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 36, D684\u2013D688 (2007). https:\/\/doi.org\/10.1093\/nar\/gkm795","journal-title":"Nucleic Acids Res."},{"key":"543_CR34","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"D.S. Wishart, Y.D. Feunang, A.C. Guo, E.J. Lo, A. Marcu, J.R. Grant, T. Sajed, D. Johnson, C. Li, Z. Sayeeda, N. Assempour, DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2018). https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res."},{"key":"543_CR35","first-page":"1","volume":"1695","author":"G Csardi","year":"2006","unstructured":"G. Csardi, T. Nepusz, The igraph software package for complex network research. InterJournal, Complex Systems 1695, 1\u20139 (2006)","journal-title":"InterJournal, Complex Systems"},{"key":"543_CR36","doi-asserted-by":"crossref","unstructured":"A. Hagberg, P. J. Swart, D. A. Schult, Exploring network structure, dynamics, and function using NetworkX. Los Alamos National Laboratory (LANL) No. LA-UR-08\u201305495 (2008).","DOI":"10.25080\/TCWV9851"},{"key":"543_CR37","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"U. Raudvere, L. Kolberg, I. Kuzmin, T. Arak, P. Adler, H. Peterson, J. Vilo, g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191\u2013W198 (2019). https:\/\/doi.org\/10.1093\/nar\/gkz369","journal-title":"Nucleic Acids Res."},{"key":"543_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep08190","volume":"5","author":"R Chuang","year":"2015","unstructured":"R. Chuang, B.A. Hall, D. Benque, B. Cook, S. Ishtiaq, N. Piterman, A. Taylor, M. Vardi, S. Koschmieder, B. Gottgens, J. Fisher, Drug target optimization in chronic myeloid leukemia using executable model of signaling. Sci. Rep. 5, 8190 (2015). https:\/\/doi.org\/10.1038\/srep08190","journal-title":"Sci. Rep."},{"key":"543_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/msb.2009.80","volume":"5","author":"Q Zhong","year":"2009","unstructured":"Q. Zhong, N. Simonis, Q.R. Li, B. Charloteaux, F. Heuze, N. Klitgord, S. Tam, H. Yu, K. Venkatesan, D. Mou, V. Swearingen, Edgetic perturbation models of human inherited disorders. Mol. Syst. Biol. 5, 321 (2009). https:\/\/doi.org\/10.1038\/msb.2009.80","journal-title":"Mol. Syst. Biol."},{"key":"543_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10887-6","volume":"10","author":"D Silverbush","year":"2019","unstructured":"D. Silverbush, R. Sharan, Network-based prediction of drug-target interactions. Nat. Commun. 10, 3015 (2019). https:\/\/doi.org\/10.1038\/s41467-019-10887-6","journal-title":"Nat. Commun."},{"key":"543_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/msb.2009.80","volume":"5","author":"Q Zhong","year":"2009","unstructured":"Q. Zhong, N. Simonis, Q.R. Li, B. Charloteaux, F. Heuze, N. Klitgord, S. Tam, H. Yu, K. Venkatesan, D. Mou, V. Swearingen, M.A. Yildirim, H. Yan, A. Dricot, D. Szeto, C. Lin, T. Hao, C. Fan, S. Milstein, D. Dupuy, R. Brasseur, D.E. Hill, M.E. Cusick, M. Vidal, Edgetic perturbation models of human inherited disorders. Mol. Syst. Biol. 5, 321 (2009). https:\/\/doi.org\/10.1038\/msb.2009.80","journal-title":"Mol. Syst. Biol."},{"key":"543_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 1\u201313 (2008). https:\/\/doi.org\/10.1186\/1471-2105-9-559","journal-title":"BMC Bioinformatics"},{"key":"543_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7658230","volume":"1","author":"X Chong","year":"2020","unstructured":"X. Chong, R. Peng, Y. Sun, L. Zhang, Z. Zhang, Identification of potential therapeutic targets in leukemia. BioMed Res. Int. 1, 7658230 (2020). https:\/\/doi.org\/10.1155\/2020\/7658230","journal-title":"BioMed Res. Int."},{"key":"543_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129474","volume":"10","author":"YF Gao","year":"2015","unstructured":"Y.F. Gao, F. Yuan, J. Liu, L.P. Li, Y.C. He, R.J. Gao, Y.D. Cai, Y. Jiang, Prediction of drug-target interactions. PLoS ONE 10, e0129474 (2015). https:\/\/doi.org\/10.1371\/journal.pone.0129474","journal-title":"PLoS ONE"},{"key":"543_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh3032","volume":"7","author":"N Han","year":"2021","unstructured":"N. Han, W. Hwang, K. Tzelepis, P. Schmerer, E. Yankova, M. MacMahon, W. Lei, N.M. Katritsis, A. Liu, U. Felgenhauer, A. Schuldt, RNA-modifying enzyme METTL3 promotes leukemia through mRNA m6A modification. Sci. Adv. 7, eabh3032 (2021). https:\/\/doi.org\/10.1126\/sciadv.abh3032","journal-title":"Sci. Adv."},{"key":"543_CR46","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/bioinformatics\/bty637","volume":"35","author":"A Valdeolivas","year":"2018","unstructured":"A. Valdeolivas, L. Tichit, C. Navarro, S. Perrin, G. Odelin, N. Levy, P. Cau, E. Remy, A. Baudot, Random walk with restart on multiplex and heterogeneous networks. Bioinformatics 35, 497\u2013505 (2018). https:\/\/doi.org\/10.1093\/bioinformatics\/bty637","journal-title":"Bioinformatics"},{"key":"543_CR47","doi-asserted-by":"publisher","DOI":"10.1088\/1742-5468\/2008\/10\/P10008","author":"D Blondel","year":"2008","unstructured":"D. Blondel, J. Guillaume, R. Lambiotte, E. Lefebvre, Fast unfolding of communities in large networks. J. Stat. Mech. (2008). https:\/\/doi.org\/10.1088\/1742-5468\/2008\/10\/P10008","journal-title":"J. Stat. Mech."},{"key":"543_CR48","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fpls.2012.00178","volume":"3","author":"F Greil","year":"2012","unstructured":"F. Greil, Network analysis in systems biology. Front. Plant Sci. 3, 178 (2012). https:\/\/doi.org\/10.3389\/fpls.2012.00178","journal-title":"Front. Plant Sci."},{"key":"543_CR49","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4411","volume":"103","author":"BB Calabretta","year":"2004","unstructured":"B.B. Calabretta, D. Perrotti, The biology of CML blast crisis. Blood 103, 4010\u20134022 (2004). https:\/\/doi.org\/10.1182\/blood-2003-12-4411","journal-title":"Blood"},{"key":"543_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/hematology.2021000240","volume":"1","author":"J How","year":"2021","unstructured":"J. How, V. Venkataraman, G.S. Hobbs, Management of chronic myeloid leukemia in 2021. Hematology Am. Soc. Hematol. Educ. Program 1, 122\u2013128 (2021). https:\/\/doi.org\/10.1182\/hematology.2021000240","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"543_CR51","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2305264","volume":"247","author":"GQ Daley","year":"1990","unstructured":"G.Q. Daley, R.A. Van Etten, D. Baltimore, Induction of chronic myelogenous leukemia in mice by the P210 BCR\/ABL gene. Science 247, 824\u2013830 (1990). https:\/\/doi.org\/10.1126\/science.2305264","journal-title":"Science"},{"key":"543_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-021-00281-x","volume":"6","author":"MT Manzari","year":"2021","unstructured":"M.T. Manzari, Y. Shamay, H. Kiguchi, N. Rosen, M. Scaltriti, D.A. Heller, Precision medicine in cancer: therapeutic advances and challenges. Nat. Rev. Mater. 6, 351\u2013370 (2021). https:\/\/doi.org\/10.1038\/s41578-021-00281-x","journal-title":"Nat. Rev. Mater."},{"key":"543_CR53","doi-asserted-by":"publisher","first-page":"10153","DOI":"10.1074\/jbc.M510940200","volume":"281","author":"J Han","year":"2006","unstructured":"J. Han, L.A. Goldstein, B.R. Gastman, H. Rabinowich, Interrelated roles for Mcl-1 and BIM in regulation of BCR-ABL-mediated survival. J. Biol. Chem. 281, 10153\u201310163 (2006). https:\/\/doi.org\/10.1074\/jbc.M510940200","journal-title":"J. Biol. Chem."},{"key":"543_CR54","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1038\/sj.onc.1208061","volume":"23","author":"M Herrant","year":"2004","unstructured":"M. Herrant, A. Jacquel, S. Marchetti, N. Belhacene, P. Colosetti, F. Luciano, P. Auberger, Cleavage of Mcl-1 by caspases facilitates apoptosis. Oncogene 23, 7863\u20137873 (2004). https:\/\/doi.org\/10.1038\/sj.onc.1208061","journal-title":"Oncogene"},{"key":"543_CR55","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.cell.2007.04.031","volume":"129","author":"H Puthalakath","year":"2007","unstructured":"H. Puthalakath, L.A. O\u2019Reilly, P. Gunn, L. Lee, P.N. Kelly, N.D. Huntington, P.D. Hughes, E.M. Michalak, J. McKimm-Breschkin, N. Motoyama, T. Gotoh, ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129, 1337\u20131349 (2007). https:\/\/doi.org\/10.1016\/j.cell.2007.04.031","journal-title":"Cell"},{"key":"543_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkj439","author":"DW Bartlett","year":"2006","unstructured":"D.W. Bartlett, M.E. Davis ME, Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. (2006). https:\/\/doi.org\/10.1093\/nar\/gkj439","journal-title":"Nucleic Acids Res."},{"key":"543_CR57","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"C. Zincarelli, S. Soltys, G. Rengo, J.E. Rabinowitz, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073\u20131080 (2008). https:\/\/doi.org\/10.1038\/mt.2008.76","journal-title":"Mol. Ther."},{"key":"543_CR58","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0154","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"H.E. Ramsey, M.A. Fischer, T. Lee, V.E. Gorska, M.P. Arrate, L. Fuller, K.L. Boyd, S.A. Strickland, J. Sensintaffar, L.J. Hogdal, G.D. Ayers, A novel BH3-mimetic, S63845, targets MCL1 in myeloid malignancies. Cancer Discov. 8, 1566\u20131581 (2018). https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0154","journal-title":"Cancer Discov."},{"key":"543_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01080-x","volume":"14","author":"H Wang","year":"2021","unstructured":"H. Wang, M. Guo, H. Wei, Y. Chen, Targeting MCL-1 in cancer: current status and perspectives. J. Hematol. Oncol. 14, 67 (2021). https:\/\/doi.org\/10.1186\/s13045-021-01080-x","journal-title":"J. Hematol. Oncol."},{"key":"543_CR60","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1158\/1535-7163.MCT-13-0077","volume":"12","author":"C Billard","year":"2013","unstructured":"C. Billard, BH3 mimetics: status of the field and new developments. Mol. Cancer Ther. 12, 1691\u20131700 (2013). https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0077","journal-title":"Mol. Cancer Ther."}],"container-title":["Nano Convergence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40580-026-00543-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40580-026-00543-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40580-026-00543-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:34:00Z","timestamp":1781645640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40580-026-00543-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1186\/s40580-026-00543-3","relation":{},"ISSN":["2196-5404"],"issn-type":[{"value":"2196-5404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.J.K. is a co-founder of Match the Hatch Biotechnology, Inc. and a consultant to PharmaResearch, Co., Ltd. N.H. is a cofounder and Chief Technology Officer of CardiaTec Bio, and a cofounder of KURE.ai. N.H. receives research funding from and collaborates with LifeArc, and has served as a consultant for DNA Link Ltd. None of these activities are directly relevant to the reported study. W.L. is currently employed by Avatrial Ltd., which works in the field of cancer therapeutics. This role began after completion of the research reported here.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"13"}}